Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in NeuroscienceGlobeNewsWire • 09/21/21
FDA Approves Samsung Bioepis and Biogen's BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna)GlobeNewsWire • 09/20/21
CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple SclerosisGlobeNewsWire • 09/17/21
Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber NeuropathyGlobeNewsWire • 09/16/21
Biogen Launches High-Dose Spinraza Trial In Evrysdi Treated Patients: What You Need To KnowBenzinga • 09/15/21
Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam)GlobeNewsWire • 09/15/21
Biogen (BIIB) Alzheimer's Drug Aduhelm Sees Slow Launch, Stock DownZacks Investment Research • 09/10/21
Biogen Inc. (BIIB) CEO Michel Vounatsos Presents at Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/09/21